A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer

Cancer of Head and Neck Clinical Trial

Official title:

A Phase II Randomized Trial Evaluating the Use of Proton Pump Inhibitors (PPIs) in Conjunction With Chemotherapy, in Patients With Recurrent Unresectable or Metastatic Cancers of the Head and Neck

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02013453
• Other study ID #: UMCC 2013.046
• Secondary ID: HUM00074951
• Status: Withdrawn
• Phase: Phase 2
• First received: December 11, 2013
• Last updated: December 1, 2014
• Start date: December 2013

Study information

• Verified date: December 2014
• Source: University of Michigan Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if the addition of proton pump inhibitors (PPIs) to standard chemotherapy can improve progression free survival in patients with head and neck cancer.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. primary completion date: December 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Males and non-pregnant, non-lactating females at least 18 years old.

• Histologically or cytologically confirmed diagnosis of SCCHN (Squamous Cell Carcinoma of the Head and Neck).

• Stage IVC (metastatic) or advanced, locally recurrent SCCHN not amenable to curative surgery or radiotherapy.

• Measurable disease as defined by RECIST (Response Evaluation Criteria in Solid Tumors) vs 1.1 (Appendix 1).

a. If the only site of measurable disease for this study is within a prior field of irradiation, then the sum of the longest diameters (SLD) of that lesion must have increased by at least 20% from the prior treatment nadir.

• ECOG Performance status (measure of health and general well being on a scale of 0 to 5 where 0 represents perfect health) < 1 (Appendix 2).

• Expected survival of at least 3 months.

• Adequate liver and renal function that is defined as Calculated creatinine clearance of <30ml/min (by Jelliffe calculator) AST (aspartate aminotransferase)/ALT (alanine aminotransferase) < 2.5 X ULN (unless there are hepatic metastasis, in which case AST/ALT within 5 X ULN) Total Bilirubin < 1.5 X ULN (Appendix 5).

• Ability to understand and willingness to sign an informed consent form.

• Willingness and ability to comply with study procedures and follow up.

• There is no restriction on number of prior therapies as long as the patient is deemed a candidate for palliative chemotherapy with one of the standard chemotherapy regimens.

• Willingness to use contraception by a method that is deemed effective by the Investigator by both male and female patients of childbearing potential and their partners throughout the treatment period and for at least 30 days following the last cycle of chemotherapy (post menopausal women must have been amenorrheal for at-least 12 months to be considered of non-childbearing potential).

Exclusion Criteria:

• Comorbidities precluding treatment with combination chemotherapy or per investigator discretion.

• Pregnancy or lactation.

• Medical or psychiatric illness that may compromise the patient's ability to tolerate the treatment or comply with the study requirements.

• Patients with another active cancer or history of another cancer in the last 3 years except those treated with curative intent such as skin cancer (other than melanoma), in situ breast or in situ cervical cancer or those treated with curative intent for any other cancer with no evidence of disease for 2 years.

• Allergy to PPI or inability to tolerate PPI.

• Patients residing in prison.

• Any investigational drug dose within 28 days of planned start of trial.

• Any concurrent standard therapy intended to treat SCCHN.

• Any symptomatic infection (bacterial, fungal or viral) as per the investigator discretion.

• Patients with uncontrolled CNS (Central Nervous System) metastases are excluded. Patients with known, previously treated CNS metastases are eligible if they are neurologically stable as per the investigating physician's clinical assessment.

• Any other condition or circumstance that would, in the opinion of the Investigator, make the patient unsuitable for participation in the study.

• Patients on Rilpivirine, Atazanavir, Indinavir and Nelfinavir will not be eligible for participation in study because of the significant drug interaction unless the patient can be switched to a different antiviral medication prior to study enrollment.

• Omeprazole can increase the serum concentration of methotrexate, clorazepate and citalopram increasing the risk of adverse effects.

• Omeprazole may result in reduction in clinical efficacy of clopidogrel and increased risk for thrombosis.

• Omeprazole when co-administered with dasatinib, bosutinib, ponatinib, erlotinib, dabrafenib and vismodegib reduces the systemic exposure to these drugs, therefore patients on these drugs should not be enrolled in the study.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cancer of Head and Neck
• Head and Neck Neoplasms

Intervention

Drug:
• Omeprazole
40mg of Omeprazole will be administered daily by mouth.
• Carboplatin
Carboplatin will be administered over 30 minutes by continuous infusion.
• 5FU
Administered by infusion.
• Paclitaxel
Administered by infusion.
• Pemetrexed
Administered by infusion.

Locations

Country	Name	City	State
United States	University of Michigan Hospital	Ann Arbor	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
University of Michigan Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to progression	The primary aim, progression-free survival, will be defined from start of treatment to date of first progression and will be tested using a Cox proportional hazard regression model with treatment arm as the only predictor.	6 months post treatment	No
Secondary	Median overall survival	Overall survival be evaluated with Cox models and will be defined from the first date of treatment to date of death.	6 months post treatment	No
Secondary	Proportion of patients that experience a response to treatment	Estimate the proportion of patients with a complete response (CR), partial response (PR), objective response (CR+PR) and clinical benefit (CR+PR+Stable disease) and compare responses between the group receiving proton pump inhibitors (PPI) and the group not receiving PPIs.	6 months post treatment	No